Merck & Co. (MRK) Stock: Slips to $148.87 Despite Strong Melanoma Trial Results With Moderna
TLDR Merck stock dips 0.67% despite a 42% drop in melanoma recurrence or death risk. Merck and Moderna’s mRNA therapy…
Market coverage 8 stories
TLDR Merck stock dips 0.67% despite a 42% drop in melanoma recurrence or death risk. Merck and Moderna’s mRNA therapy…
Moderna and Merck are expected to share the Phase 3 data for their experimental cancer vaccine this weekend at a…